Natasha Kekre, Haesook T Kim, Julia Hofer, Vincent T Ho, John Koreth, Philippe Armand, Sarah Nikiforow, Mahasweta Gooptu, Rizwan Romee, Edwin P Alyea, Prashant Nageshwar, Brett Glotzbecker, Areej El-Jawahri, Zachariah DeFilipp, Robert J Soiffer, Joseph H Antin, Yi-Bin Chen, Corey Cutler
The α4ß7 integrin is upregulated on naive and memory T cell subsets in patients who subsequently develop gastrointestinal (GI) acute GVHD. Natalizumab (Tysabri® , Biogen Inc.) acts against the α4 subunit that mediates homing of lymphocytes to the GI tract. We initiated a phase II study of natalizumab with corticosteroids for initial treatment of acute GI GVHD. In total, 300 mg IV of natalizumab was given, with steroids initiated up to 3 days prior. Twenty-one subjects were treated, median age was 63 years (range 38-74), and 15 (71%) were male...
September 8, 2020: Bone Marrow Transplantation